Welcome to our dedicated page for Repare Therapeutics news (Ticker: RPTX), a resource for investors and traders seeking the latest updates and insights on Repare Therapeutics stock.
Repare Therapeutics Inc (RPTX) is a clinical-stage biotechnology company pioneering precision oncology therapies through its synthetic lethality platform and CRISPR-enabled target discovery. This page aggregates official announcements, research breakthroughs, and strategic developments critical for understanding the company's progress in developing targeted cancer treatments.
Investors and researchers will find comprehensive updates on clinical trial milestones, regulatory filings, and scientific collaborations. The curated news collection includes updates on therapeutic candidates, partnership agreements, and peer-reviewed research findings, providing a centralized hub for tracking RPTX's contributions to oncology innovation.
Key content areas cover clinical-stage developments, research publications, and strategic partnerships that demonstrate the company's scientific rigor. All materials are sourced from verified corporate communications and reputable industry publications to ensure reliability.
Bookmark this page for streamlined access to Repare Therapeutics' latest advancements in CRISPR-based drug discovery and precision oncology solutions. Check back regularly for real-time insights into their mission to develop therapies targeting genetic vulnerabilities in cancer cells.
Repare Therapeutics (Nasdaq: RPTX) has dosed the first patient in the expansion of its TRESR clinical trial, focusing on camonsertib monotherapy for non-small cell lung cancer (NSCLC) with ATM mutations. This expansion follows the rapid return of global rights to Repare. The TRESR trial aims to address the unmet need of over 5,000 patients with recurrent NSCLC in the US, UK, and top EU markets. Current treatments offer progression-free survival of around four months. The trial will enroll up to 20 patients to evaluate the efficacy of camonsertib at the recommended Phase 2 dose, with data expected in 2025.
Repare Therapeutics (Nasdaq: RPTX) has received Fast Track designation from the FDA for its combination therapy of lunresertib and camonsertib for treating platinum-resistant ovarian cancer in patients with specific genetic profiles (CCNE1 amplification, FBXW7, or PPP2R1A mutations). This treatment is currently in Phase 1 dose expansion trials. The FDA previously granted Fast Track designation for the same combination in treating endometrial cancer. Repare plans to present data from these trials in the fourth quarter of 2024, involving 20-30 patients each for ovarian and endometrial cancers. The Fast Track designation aims to expedite the development and review processes to bring significant new therapies to patients sooner.
Repare Therapeutics (Nasdaq: RPTX), a clinical-stage precision oncology company, announced that its senior management will participate in the Goldman Sachs 45th Annual Global Healthcare Conference.
The event will take place on June 10, 2024, at 2:40 p.m. Eastern Time in Miami, FL. The session will include a fireside chat, and a live webcast will be available on Repare's investor relations website.
The webcast replay will be accessible for 90 days post-event.
Repare Therapeutics (Nasdaq: RPTX) announced that initial data from its Phase 1 MINOTAUR study will be presented at the European Society of Medical Oncology (ESMO) GI Congress 2024. The study evaluates the efficacy of lunresertib (RP-6306) in combination with FOLFIRI for treating advanced solid tumors. This presentation is scheduled for June 27, 2024, at 3:35 PM CEST in Munich, Germany. The study aims to offer new insights into advanced gastrointestinal cancer treatments.
Repare Therapeutics Inc. reported financial results for Q1 2024, highlighting clinical progress in various programs. FDA agrees with RP2D for lunresertib plus camonsertib combo. Phase 2 TRESR expansion and Phase 1 LIONS monotherapy trial initiated. $237.0M in cash to fund operations till mid-2026. Camonsertib rights regained, new trial initiations, and board appointment announced. Revenue from collaboration agreements increased to $52.4M. Net income for Q1 2024 was $13.2M.
Repare Therapeutics and Debiopharm have dosed the first patient in the Phase 1/1b MYTHIC trial, evaluating the combination of PKMYT1 and WEE1 inhibition. This collaboration aims to assess safety, pharmacokinetics, and preliminary clinical activity of lunresertib and Debio 0123, showing promise for cancer patients.
FAQ
What is the current stock price of Repare Therapeutics (RPTX)?
What is the market cap of Repare Therapeutics (RPTX)?
